🇺🇸 FDA
Company

Protalix

Protalix BioTherapeutics

PLX biotech USA

Quick answer

Protalix is a biotech company (PLX) headquartered in HACKENSACK, NJ, USA with 21 tracked pipeline programs.

Pipeline (21)

project

PL2200 Aspirin Capsules

Diabetes Mellitus, Type 2

Phase 3 · small_molecule · completed

2 trials project

PRX-102

Fabry Disease

Phase 3 · small_molecule · completed

2 trials project

PRX-102 (pegunigalsidase alfa)

Fabry Disease

Phase 3 · mab · completed

3 trials project

Pegunigalsidase alfa

Fabry Disease

Phase 3 · mab · completed

1 trials project

AIR DNase™

Cystic Fibrosis

Phase 2 · small_molecule · active

1 trials project

Ibuprofen-PC

Osteoarthritis

Phase 2 · small_molecule · completed

1 trials project

Naproxen

Healthy Volunteers

Phase 2 · small_molecule · completed

1 trials project

OPRX-106

Ulcerative Colitis

Phase 2 · small_molecule · active

1 trials project

PL2200

Gastroduodenal Ulceration

Phase 2 · small_molecule · completed

1 trials project

PL3100

Gastroduodenal Ulcerations

Phase 2 · small_molecule · completed

1 trials project

PRX-112

Gaucher Disease

Phase 2 · small_molecule · completed

2 trials project

PRX-115

Gout

Phase 2 · mab · active

2 trials project

acetylsalicylic acid

Upper Gastrointestinal Mucosal Damage

Phase 2 · small_molecule · completed

1 trials project

AIR DNase

Cystic Fibrosis (CF)

Phase 1 · small_molecule · completed

1 trials project

Aspirin

Bioequivalence

Phase 1 · small_molecule · completed

1 trials project

Human Glucocerebrosidase (prGCD)

Gaucher Disease

Phase 1 · small_molecule · completed

1 trials project

OPRX-106

Human Volunteer

Phase 1 · small_molecule · completed

1 trials project

PL2200 fasted

Healthy

Phase 1 · small_molecule · completed

1 trials project

PRX-105

Organophosphate Exposure

Phase 1 · small_molecule · completed

1 trials project

Pharmaceutical-lipid aspirin (PL-ASA)

Bioequivalence

Phase 1 · small_molecule · completed

1 trials project

PL-ASA

Healthy Volunteers

Approved · small_molecule · completed

1 trials

Patents (8)

patent

US 12385026

Stabilized alpha-galactosidase and uses thereof

Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12194079

Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosid

Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11814657

Modified DNase and uses thereof

Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11225648

Modified DNase and uses thereof

Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10870842

Stabilized alpha-galactosidase and uses thereof

Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10730925

Chimeric polypeptides, polynucleotides encoding same, cells expressing same and

Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10280414

Stabilized α-galactosidase and uses thereof

Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10087232

Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)